Fed Circuit spurns bid to review Hatch-Waxman Act venue limits

The US Court of Appeals for the Federal Circuit has dismissed an attempt by Valeant Pharmaceuticals to overturn a ruling that restricted where Hatch-Waxman Act patent lawsuits can be filed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Hatch-Waxman amendment: a Hobson’s choice

8 August 2018 If enacted by Congress, the proposed amendment to the Hatch-Waxman Act would spell trouble for generic pharmaceutical companies seeking to take on brand competitors in patent litigation, says Janine Carlan of Arent Fox.

Americas

Senator proposes Hatch-Waxman change to boost generic development

15 June 2018 US Senator Orrin Hatch has proposed an amendment to the Hatch-Waxman Act to “restore the careful balance” the act struck to incentivise generic drug development.

Americas

Hatch-Waxman can’t offer ‘safe harbour’ defence in gene therapy case

6 January 2022 Sarepta Therapeutics won’t be able to rely on a “safe harbour” provision to protect its gene therapy invention from a patent infringement suit from biotech Regenxbio and the University of Pennsylvania, a Delaware court has ruled.

More on this story

Americas

Hatch-Waxman amendment: a Hobson’s choice

Americas

Senator proposes Hatch-Waxman change to boost generic development

15 June 2018 US Senator Orrin Hatch has proposed an amendment to the Hatch-Waxman Act to “restore the careful balance” the act struck to incentivise generic drug development.

Americas

Hatch-Waxman can’t offer ‘safe harbour’ defence in gene therapy case

More on this story

Americas

Hatch-Waxman amendment: a Hobson’s choice

Americas

Senator proposes Hatch-Waxman change to boost generic development

15 June 2018 US Senator Orrin Hatch has proposed an amendment to the Hatch-Waxman Act to “restore the careful balance” the act struck to incentivise generic drug development.

Americas

Hatch-Waxman can’t offer ‘safe harbour’ defence in gene therapy case